FDA Adverse Event Death Summary report: N

EVOLUT FX PLUS VALVE

MDR report key: 22472926 · Received July 10, 2025

Report

Report Number
2025587-2025-04909
Event Type
Death
Date Received
July 10, 2025
Date of Event
June 26, 2025
Report Date
September 18, 2025
Manufacturer
MEDTRONIC MEXICO S. DE R.L. DE CV
Product Code
NPT
UDI-DI
00763000716141
PMA / PMN Number
P130021
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
CA, US
Reporter Occupation
PHYSICIAN
Health Professional
Yes

Narratives

Additional Manufacturer Narrative · 0

SECTION D REFERENCES THE MAIN COMPONENT OF THE SYSTEM. OTHER MEDICAL PRODUCTS IN USE DURING THE EVENT INCLUDE: BRAND NAME EVOLUT FX PLUS VALVE; PRODUCT ID EVFXPLUS-29 (SERIAL: (B)(6)); PRODUCT TYPE: 0195-HEART VALVES; IMPLANT DATE (B)(6) 2025. MEDTRONIC SUBMITS THIS REPORT TO COMPLY WITH FDA REGULATIONS 21 CFR PARTS 4 AND 803. MEDTRONIC HAS MADE REASONABLE EFFORTS TO PROVIDE AS MUCH RELEVANT INFORMATION AS IS AVAILABLE TO THE COMPANY AS OF THE SUBMISSION DATE OF THIS REPORT. THIS REPORT DOES NOT CONSTITUTE AN ADMISSION OR A CONCLUSION BY FDA, MEDTRONIC, OR ITS EMPLOYEES THAT THE DEVICE, MEDTRONIC, OR ITS EMPLOYEE CAUSED OR CONTRIBUTED TO THE EVENT DESCRIBED IN THE REPORT. ANY REQUIRED FIELDS THAT ARE UNPOPULATED ARE BLANK BECAUSE THE INFORMATION IS CURRENTLY UNKNOWN OR UNAVAILABLE. MEDTRONIC WILL SUBMIT A SUPPLEMENTAL REPORT IF ADDITIONAL RELEVANT INFORMATION BECOMES KNOWN.

Additional Manufacturer Narrative · 0

UPDATED DATA: B5. ADDED SECOND PARAGRAPH. D3. D4. H4. H6. MEDTRONIC SUBMITS THIS REPORT TO COMPLY WITH FDA REGULATIONS 21 CFR PARTS 4 AND 803. MEDTRONIC HAS MADE REASONABLE EFFORTS TO PROVIDE AS MUCH RELEVANT INFORMATION AS IS AVAILABLE TO THE COMPANY AS OF THE SUBMISSION DATE OF THIS REPORT. THIS REPORT DOES NOT CONSTITUTE AN ADMISSION OR A CONCLUSION BY FDA, MEDTRONIC, OR ITS EMPLOYEES THAT THE DEVICE, MEDTRONIC, OR ITS EMPLOYEE CAUSED OR CONTRIBUTED TO THE EVENT DESCRIBED IN THE REPORT. ANY REQUIRED FIELDS THAT ARE UNPOPULATED ARE BLANK BECAUSE THE INFORMATION IS CURRENTLY UNKNOWN OR UNAVAILABLE. MEDTRONIC WILL SUBMIT A SUPPLEMENTAL REPORT IF ADDITIONAL RELEVANT INFORMATION BECOMES KNOWN.

Additional Manufacturer Narrative · 0

THIS IS A SYSTEM REPORT. THE SECTION D INFORMATION IS FOR THE PRIMARY DEVICE, WHICH WAS IN USE WITH THE FOLLOWING: BRAND NAME: EVOLUTFX DELIVERY CATHETER SYSTEM (DCS), PRODUCT ID: D-EVOLUTFX-2329, LOT: 0012328691, USE BY DATE: 2026-06-24, UDI: (B)(4). UPDATED: B2, B5, D3, D4, D6A, H4, H6, H11. MEDTRONIC SUBMITS THIS REPORT TO COMPLY WITH FDA REGULATIONS 21 CFR PARTS 4 AND 803. MEDTRONIC HAS MADE REASONABLE EFFORTS TO PROVIDE AS MUCH RELEVANT INFORMATION AS IS AVAILABLE TO THE COMPANY AS OF THE SUBMISSION DATE OF THIS REPORT. THIS REPORT DOES NOT CONSTITUTE AN ADMISSION OR A CONCLUSION BY FDA, MEDTRONIC, OR ITS EMPLOYEES THAT THE DEVICE, MEDTRONIC, OR ITS EMPLOYEE CAUSED OR CONTRIBUTED TO THE EVENT DESCRIBED IN THE REPORT. ANY REQUIRED FIELDS THAT ARE UNPOPULATED ARE BLANK BECAUSE THE INFORMATION IS CURRENTLY UNKNOWN OR UNAVAILABLE. MEDTRONIC WILL SUBMIT A SUPPLEMENTAL REPORT IF ADDITIONAL RELEVANT INFORMATION BECOMES KNOWN.

Description of Event or Problem · 0

IT WAS REPORTED THAT PRIOR TO THE IMPLANT OF THIS EVFXPLUS-29, A PRE-IMPLANT BALLOON AORTIC VALVULOPLASTY WAS PERFORMED TWICE USING A 20 MM NON-MEDTRONIC BALLOON. THE VALVE AND DELIVERY CATHETER SYSTEM WERE INSERTED INTO THE PATIENT AND ADVANCED TO THE ANNULUS. UPON DEPLOYMENT TO 80%, THE PATIENT'S BLOOD PRESSURE DROPPED. AS A RESULT, LIGHT CARDIOPULMONARY RESUSCITATION (CPR) COMPRESSIONS WERE COMMENCED DURING THE FINAL DEPLOYMENT. SUBSEQUENTLY, A PERICARDIAL EFFUSION WAS IDENTIFIED AND PERICARDIOCENTESIS WAS PERFORMED AS AN INTERVENTION. CARDIOPULMONARY RESUSCITATION CONTINUED WITH "CODE BLUE" PROTOCOL INITIATED. THE PATIENT DIED DESPITE INTERVENTION. PER THE PHYSICIAN, THE PROCEDURE CONTRIBUTED TO THE DEATH. IT IS UNKNOWN WHETHER THE DEVICE CONTRIBUTED TO THE CAUSE OF DEATH.

Description of Event or Problem · 0

IT WAS REPORTED THAT PRIOR TO THE IMPLANT OF THIS EVFXPLUS-29, A PRE-IMPLANT BALLOON AORTIC VALVULOPLASTY WAS PERFORMED TWICE USING A 20 MM NON-MEDTRONIC BALLOON. THE VALVE AND DELIVERY CATHETER SYSTEM WERE INSERTED INTO THE PATIENT AND ADVANCED TO THE ANNULUS. UPON DEPLOYMENT TO 80%, THE PATIENT'S BLOOD PRESSURE DROPPED. AS A RESULT, LIGHT CARDIOPULMONARY RESUSCITATION (CPR) COMPRESSIONS WERE COMMENCED DURING THE FINAL DEPLOYMENT. SUBSEQUENTLY, A PERICARDIAL EFFUSION WAS IDENTIFIED AND PERICARDIOCENTESIS WAS PERFORMED AS AN INTERVENTION. CARDIOPULMONARY RESUSCITATION CONTINUED WITH "CODE BLUE" PROTOCOL INITIATED. THE PATIENT DIED DESPITE INTERVENTION. PER THE PHYSICIAN, THE PROCEDURE CONTRIBUTED TO THE DEATH. IT IS UNKNOWN WHETHER THE DEVICE CONTRIBUTED TO THE CAUSE OF DEATH. ADDITIONAL INFORMATION WAS RECEIVED INDICATING THAT THE CAUSE OF DEATH WAS AN ANNULAR RUPTURE.

Description of Event or Problem · 0

IT WAS REPORTED THAT PRIOR TO THE IMPLANT OF THIS EVFXPLUS-29, A PRE-IMPLANT BALLOON AORTIC VALVULOPLASTY WAS PERFORMED TWICE USING A 20 MM NON-MEDTRONIC BALLOON. THE VALVE AND DELIVERY CATHETER SYSTEM WERE INSERTED INTO THE PATIENT AND ADVANCED TO THE ANNULUS. UPON DEPLOYMENT TO 80%, THE PATIENT'S BLOOD PRESSURE DROPPED. AS A RESULT, LIGHT CARDIOPULMONARY RESUSCITATION (CPR) COMPRESSIONS WERE COMMENCED DURING THE FINAL DEPLOYMENT. SUBSEQUENTLY, A PERICARDIAL EFFUSION WAS IDENTIFIED AND PERICARDIOCENTESIS WAS PERFORMED AS AN INTERVENTION. CARDIOPULMONARY RESUSCITATION CONTINUED WITH "CODE BLUE" PROTOCOL INITIATED. THE PATIENT DIED DESPITE INTERVENTION. PER THE PHYSICIAN, THE PROCEDURE CONTRIBUTED TO THE DEATH. IT IS UNKNOWN WHETHER THE DEVICE CONTRIBUTED TO THE CAUSE OF DEATH. ADDITIONAL INFORMATION WAS RECEIVED INDICATING THAT THE CAUSE OF DEATH WAS AN ANNULAR RUPTURE. ADDITIONAL INFORMATION WAS RECEIVED THAT PER THE PHYSICIAN, THE VALVE CAUSED THE ANNULAR RUPTURE.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
774248 EVOLUT FX PLUS VALVE AORTIC VALVE, PROSTHESIS, PERCUTANEOUSLY DELIV NPT MEDTRONIC MEXICO S. DE R.L. DE CV EVFXPLUS-29 0012328691 00763000716141

Patients

Seq Age Sex Outcome Treatment
1 76 YR Male Death| R SEE H11.